WFDC2 and ovarian cancer: HE4 is reported to be sensitive for assessing hormonal treatment and robust for menstrual cycle variation; therefore, HE4 is potentially superior to CA125 as a marker for identifying women with endometriosis at risk of developing ovarian cancer [13].